Quarterly report pursuant to Section 13 or 15(d)

LICENSES ACQUIRED (Details)

v3.24.2.u1
LICENSES ACQUIRED (Details) - USD ($)
$ in Millions
1 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Jul. 31, 2020
D F D Agreement      
LICENSES ACQUIRED      
Amount payable $ 10.0    
D F D Agreement | Minimum      
LICENSES ACQUIRED      
Percentage of royalties payable on net sales 10.00%    
D F D Agreement | Maximum      
LICENSES ACQUIRED      
Threshold additional contingent regulatory and commercial milestone payments payable $ 155.0    
Percentage of royalties payable on net sales 20.00%    
Asset purchase agreement | Qbrexza      
LICENSES ACQUIRED      
Age of patients   9 years  
Asset purchase agreement | Royalty payment percentage for first two years | Qbrexza      
LICENSES ACQUIRED      
Period of royalty payments   2 years  
Asset purchase agreement | Minimum | Royalty payment percentage for first two years | Qbrexza      
LICENSES ACQUIRED      
Percent of royalty payments   30.00%  
Asset purchase agreement | Minimum | Royalty payment percentage for thereafter | Qbrexza      
LICENSES ACQUIRED      
Percent of royalty payments   12.00%  
Asset purchase agreement | Maximum | Royalty payment percentage for first two years | Qbrexza      
LICENSES ACQUIRED      
Percent of royalty payments   40.00%  
Asset purchase agreement | Maximum | Royalty payment percentage for thereafter | Qbrexza      
LICENSES ACQUIRED      
Percent of royalty payments   19.00%  
Asset purchase agreement | Eli Lilly and Company | Qbrexza      
LICENSES ACQUIRED      
Upfront fees   $ 12.5  
Milestone payments payable   $ 144.0  
License and supply agreement With DRL | Accutane      
LICENSES ACQUIRED      
Amount of expense agreed to pay under the agreement     $ 5.0
Contingent amount payable     $ 17.0
Term of accutane     10 years
Termination accutane agreement period     180 days